We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

66 hedge funds and large institutions have $245M invested in Xenon Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

69% more capital invested

Capital invested by funds: $145M → $245M (+$100M)

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

22% more funds holding

Funds holding: 54 → 66 (+12)

9.87% more ownership

Funds ownership: 62.44% → 72.3% (+9.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
66
Holders Change
+12
Holders Change %
+22.22%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
19
Reduced
14
Closed
3
Calls
$253K
Puts
–
Net Calls
+$253K
Net Calls Change
+$252K

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.57M
2
NMC
NEA Management Company
Maryland
+$4.1M
3
ACM
Aquilo Capital Management
California
+$2.26M
4
ACP
Acuta Capital Partners
California
+$2.26M
5
BI
BVF Inc
California
+$2.18M

Top Sellers

1
BlackRock
BlackRock
New York
-$2.31M
2
DCM
DAFNA Capital Management
California
-$861K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$728K
4
Squarepoint
Squarepoint
New York
-$579K
5
AA
ALPS Advisors
Colorado
-$463K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$31.5M – – –
BI
2
BVF Inc
California
$25.6M +$2.18M +207,475 +12%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$25.2M +$6.57M +625,000 +48%
EAM
4
Eventide Asset Management
Massachusetts
$16.7M – – –
ACM
5
Aquilo Capital Management
California
$15.3M +$2.26M +215,209 +23%
Capital International Investors
6
Capital International Investors
California
$13.8M – – –
NMC
7
NEA Management Company
Maryland
$13M +$4.1M +389,444 +65%
Capital World Investors
8
Capital World Investors
California
$12.6M – – –
ACP
9
Acuta Capital Partners
California
$12M +$2.26M +215,000 +31%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$11.2M -$728K -69,200 -7%
O
11
OrbiMed
New York
$8.32M – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$7.81M +$1.13M +107,077 +22%
PHP
13
Parkman Healthcare Partners
Connecticut
$7.71M +$6.19M +588,059 New
GPCM
14
Granite Point Capital Management
Massachusetts
$3.57M -$252K -23,957 -8%
DCM
15
DAFNA Capital Management
California
$3.26M -$861K -81,813 -25%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$3.23M -$41.9K -3,987 -2%
IC
17
Ikarian Capital
Texas
$3.19M +$2.56M +243,470 New
Citadel Advisors
18
Citadel Advisors
Florida
$3.04M -$419K -39,820 -15%
EP
19
Eversept Partners
New York
$2.83M – – –
DMK
20
David M. Knott
$2.56M +$87.8K +8,346 +4%
AGA
21
Altrinsic Global Advisors
Connecticut
$2.36M – – –
SCM
22
Soleus Capital Management
Connecticut
$2.12M +$1.7M +161,600 New
AS
23
Altshuler Shaham
Israel
$1.98M – – –
GIM
24
Granahan Investment Management
Massachusetts
$1.4M +$4K +380 +0.4%
TCM
25
Tekla Capital Management
Massachusetts
$1.27M +$1.02M +96,961 New
1
2 3

XENE Hedge Fund Activity: Q4 2019 in Review

66 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2019, worth a combined $245M — up 69% from $145M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new XENE positions and 3 closed out — a net gain of 12 holders — while 19 added to existing stakes and 14 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $6.57M. The largest seller was BlackRock, exiting entirely with an estimated $2.31M sold.

  • 66 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $245M of Xenon Pharmaceuticals stock for Q4 2019, up 69% quarter-over-quarter.
  • 15 funds opened new Xenon Pharmaceuticals positions in Q4 2019 and 3 closed out, a net change of +12 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2019 was Adage Capital Partners, an estimated $6.57M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2019 was BlackRock, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2019.